Skip to main content
We Study Billionaires

TIP811: OTC Markets (OTCM): A Picks and Shovels Play in Modern Capital Markets w/ Kyle Grieve & Shawn O'Malley

81 min episode · 3 min read

Episode

81 min

Read time

3 min

Topics

Investing, Fundraising & VC, Leadership

AI-Generated Summary

Key Takeaways

  • Quasi-monopoly positioning: OTCM operates as the only viable US listing venue for non-SEC-registered foreign companies and businesses too small for NYSE or Nasdaq. This structural exclusivity drives 90–95% renewal rates across its OTCQB and OTCQX tiers, with corporate service customers averaging 14–20 year tenures and lifetime value between $350,000–$500,000 per issuer before accounting for annual 3–5% price escalators.
  • Three-segment revenue structure: OTC Link (trading infrastructure, 21% of revenue, ~$26M) earns subscription and per-transaction fees from broker-dealers. Market Data Licensing (40%, ~$40M) sells recurring data licenses to Bloomberg, Refinitiv, and direct users. Corporate Services (39%, ~$49M) charges flat annual listing fees regardless of market cap or volume, making it the least cyclical segment and the most defensible revenue stream.
  • Operating leverage with minimal headcount: Revenue nearly doubled from $68M in 2020 to $125M today while headcount grew from 102 to just 130 employees. Revenue per employee rose from $666K to $961K. Free cash flow compounded at 14% annually over a decade versus 11% revenue growth, signaling embedded operating leverage — a three-percentage-point spread that reflects fixed-cost dominance in a scalable infrastructure model.
  • Negative working capital as a financing advantage: OTCM carries $33.6M in customer prepayments as non-interest-bearing current liabilities, making invested capital effectively zero or negative. This renders standard ROIC calculations misleading. Return on equity runs at 102% GAAP, with a ten-year average near 94%. The business distributes nearly 100% of net operating profit after tax — $29.6M in dividends and $2.9M in buybacks in 2025.
  • Regulatory moat cuts both ways: OTCM's competitive position depends heavily on SEC rules barring NYSE and Nasdaq from listing non-SEC-registered securities. A venture exchange framework — already proposed by Nasdaq in 2019 — or mandatory SEC re-registration rules could materially impair all three segments simultaneously. Investors should monitor SEC rulemaking as the single highest-impact risk, not competitive disruption from technology or data providers.

What It Covers

Kyle Grieve and Shawn O'Malley analyze OTC Markets Group (OTCM), a 130-person company running infrastructure for 12,000+ securities — more than NYSE and Nasdaq combined. The episode covers OTCM's three business segments, competitive moat, regulatory risks, management quality, and a valuation model projecting ~16% IRR plus a 4% dividend yield from current prices.

Key Questions Answered

  • Quasi-monopoly positioning: OTCM operates as the only viable US listing venue for non-SEC-registered foreign companies and businesses too small for NYSE or Nasdaq. This structural exclusivity drives 90–95% renewal rates across its OTCQB and OTCQX tiers, with corporate service customers averaging 14–20 year tenures and lifetime value between $350,000–$500,000 per issuer before accounting for annual 3–5% price escalators.
  • Three-segment revenue structure: OTC Link (trading infrastructure, 21% of revenue, ~$26M) earns subscription and per-transaction fees from broker-dealers. Market Data Licensing (40%, ~$40M) sells recurring data licenses to Bloomberg, Refinitiv, and direct users. Corporate Services (39%, ~$49M) charges flat annual listing fees regardless of market cap or volume, making it the least cyclical segment and the most defensible revenue stream.
  • Operating leverage with minimal headcount: Revenue nearly doubled from $68M in 2020 to $125M today while headcount grew from 102 to just 130 employees. Revenue per employee rose from $666K to $961K. Free cash flow compounded at 14% annually over a decade versus 11% revenue growth, signaling embedded operating leverage — a three-percentage-point spread that reflects fixed-cost dominance in a scalable infrastructure model.
  • Negative working capital as a financing advantage: OTCM carries $33.6M in customer prepayments as non-interest-bearing current liabilities, making invested capital effectively zero or negative. This renders standard ROIC calculations misleading. Return on equity runs at 102% GAAP, with a ten-year average near 94%. The business distributes nearly 100% of net operating profit after tax — $29.6M in dividends and $2.9M in buybacks in 2025.
  • Regulatory moat cuts both ways: OTCM's competitive position depends heavily on SEC rules barring NYSE and Nasdaq from listing non-SEC-registered securities. A venture exchange framework — already proposed by Nasdaq in 2019 — or mandatory SEC re-registration rules could materially impair all three segments simultaneously. Investors should monitor SEC rulemaking as the single highest-impact risk, not competitive disruption from technology or data providers.
  • Valuation and entry point framework: At current prices (~$54/share), applying 12% annual net income growth from a 2025 base of $31M reaches ~$55M by 2030. A 25x earnings multiple — consistent with OTCM's decade-long average — implies a $1.3B market cap and ~$113/share, yielding ~16% IRR plus a ~4% dividend yield. Waiting for the price-to-earnings ratio to drop below 20x provides additional margin of safety and multiple expansion upside.

Notable Moment

Despite OTCM covering more securities than NYSE and Nasdaq combined and compounding free cash flow at 14% annually for a decade with zero debt, its market cap remains in the hundreds of millions — a fraction of S&P Global, which relies partly on OTCM as a raw data supplier. The valuation gap relative to its infrastructure role stands out as a structural anomaly.

Know someone who'd find this useful?

Episode Transcript

You're listening to TIP. Every time you buy a stock that doesn't trade on the New York Stock Exchange or Nasdaq, a foreign company, a small cap, a pink sheet name, there's a company in the background collecting a toll. You've probably never thought about them, and they've never thought about making you think about them. That company is OTC Markets, and here's a wild fact. The platform they run covers over 12,000 secondurities, more than both major exchanges combined, yet the whole operation runs on fewer than a 130 people. Today, we find out how a business that most investors have never even heard of has quietly compounded free cash flow at 14% annually over a decade and whether it can continue doing it. Since 2014, with more than 200,000,000 downloads, we have interviewed the world's best investors, studied deeply the principles of value investing, and uncovered many compelling investment opportunities. We focus on understanding businesses and intrinsic value, investing accordingly, and sharing everything we learn with you. This show is not investment advice. It's intended for informational and entertainment purposes only. All opinions expressed by hosts and guests are solely their own, and they may have investments in the securities discussed. Now for your hosts, Sean O'Malley and Kyle Grieve. Hey, folks. Today, we will continue our hunt for intrinsic value by going deep into the infrastructure and operations that underpin financial markets with a company called OTC Markets Group. And if you've ever invested in The US in companies not listed on the New York Stock Exchange or NASDAQ, there's a pretty good chance, whether you realize it or not, that you've come across OTC Markets before, where OTC stands for over the counter. And in market cap terms, it is a small company. I think it's fair to say it's a hugely important role in the financial system and that has enabled the company to generate some really eye popping financial results. That's right. So I remember listening to one of Monique Pariah's chats a number of years ago, where he said that one of his favorite ways of finding a new investment idea was to simply just find a wide moat business in one country that was being applied to yet another country. Now OTC Markets doesn't quite fit this bill as it's operational in The US, but it's among a very small number of capital market infrastructure plays that are available and it has very, very unique competitive advantages. Now, OTCM also has a very rich history. So its current CEO Cromwell Colson bought Pink Sheets with an investor group way back in 1997 to bring the business into the digital age. And as he developed the business, they went through a number of rebrandings going from the National Quotation Bureau to Pink Sheets to Pink Sheets OTC and finally to OTC Markets Group. And as they've evolved, they've shown just terrific sustainable growth. The numbers really just speak for themselves. So OTCM boasts …

Get the full transcript (16,638 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all We Study Billionaires transcripts →

You just read a 3-minute summary of a 78-minute episode.

Get We Study Billionaires summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from We Study Billionaires

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Investing Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into We Study Billionaires.

Every Monday, we deliver AI summaries of the latest episodes from We Study Billionaires and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime